A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

Clinical Infectious Diseases

Volumn 33, Issue 9, 2001, Pages 1529-1535

  Villanueva, Alvaro ^a   Arathoon, Eduardo G ^b   Gotuzzo, Eduardo ^c   Berman, Rayanne S ^d   DiNubile, Mark J ^d   Sable, Carole A ^d  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN B DEOXYCHOLATE; ANTIRETROVIRUS AGENT; CASPOFUNGIN; COTRIMOXAZOLE; CREATININE; ECHINOCANDIN B DERIVATIVE; KETOCONAZOLE; NYSTATIN; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; ESOPHAGOSCOPY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; HYPOKALEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDIASIS; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; DRUG TOLERANCE; ESOPHAGITIS; ESOPHAGOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC;

EID: 0035503456     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/323401     Document Type: Article

References (35)

1. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
2. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome
3. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance
4. Practice guidelines for the treatment of candidiasis
5. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
6. Amphotericin B colloidal dispersion for the treatment of candidemia in immunocompromised patients
7. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates
8. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and resistant Candida species
9. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species
10. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
11. Current and future antifungal therapy: New targets for antifungal agents
12. Antifungal agents: Chemotherapeutic targets and immunologic strategies
13. A randomized, double-blind, multicenter trial of MK-0991 (L-743872) versus amphotericin B (AMB) in the treatment of Candida esophagitis in adults
14. Developing improved observational methods for evaluating therapeutic effectiveness
15. Randomized trials or observational tribulations?
16. Reporting the study populations of clinical trials. Clear transmission or static on the line?
17. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain
18. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients
19. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidlasis due to Candida albicans
20. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidlasis
21. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fiuconazole, itraconazole, and Candida infections
22. Failure of all antifungal therapy for infection due to Candida albicans: A new AIDS-related problem?
23. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance
24. Comparative in vitro susceptibility of clinical trial isolates to the echinocandin antifungal caspofungin (Cancidas, MK-0991)
25. Antifungal agents. Part I: Amphotericin B preparations and flucytosine
26. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients
27. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection
28. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS
29. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients
30. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients
31. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
32. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HlIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro
33. The role of Candida dubliniensis in oral candidiasis in human immunodeficiency virus-infected individuals
34. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
35. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872